GLP-1 Market
LLY $1274.22 ▼ -2.5% NVO $39.03 ▼ -1.0% PFE $30.01 ▼ -1.3% VKTX $24.40 ▼ -5.5% KLRA $12.85 ▼ -3.2% GPCR $21.19 ▼ -3.4% RHHBY $61.17 ▲ +2.6%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Florbetaben F18

Florbetaben F18

Company
Lantheus Germany GmbH
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
9 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

9 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 24, 2026

Find a Clinical Trial Near Me

See recruiting studies for Florbetaben F18 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT04396873

    PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

    Not yet reported National Institute of Mental Health (NIMH) 184 participants Est. completion 2030-10-03 1 site
    Other conditions: Parkinson's Disease, Dementia, Alzheimer's Disease, ALS, Mild Cognitive Impairment
    View official trial listing →
  • Recruiting NCT NCT04576793

    Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease

    Not yet reported Columbia University 100 participants Est. completion 2027-05-31 1 site
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Recruiting NCT NCT06032026

    Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15

    Not yet reported University of Pennsylvania 70 participants Est. completion 2028-07-31 1 site Stand-alone
    Other conditions: Tauopathies
    View official trial listing →
  • Recruiting NCT NCT06091319

    Florbetaben for Imaging of Vascular Amyloid

    Ottawa Heart Institute Research Corporation 30 participants Est. completion 2026-12-01 1 site
    Cardiovascular disease Other conditions: Acute Coronary Syndrome, Transient Ischemic Attack, Atherosclerosis of Artery
    View official trial listing →
  • Recruiting NCT NCT06303921

    Study of Biodistribution, Metabolism, Excretion and Brain Uptake11C-M503

    Not yet reported University of Pennsylvania 70 participants Est. completion 2029-02 3 sites Stand-alone
    Other conditions: Tauopathies
    View official trial listing →
  • Recruiting NCT NCT06932809

    Study of Biodistribution, Metabolism, Excretion and Brain Uptake 18F-JSS20-183A

    Not yet reported University of Pennsylvania 90 participants Est. completion 2030-04 2 sites Stand-alone
    Other conditions: Tauopathies
    View official trial listing →
  • Recruiting NCT NCT07169630

    PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)

    Not yet reported National Institute of Mental Health (NIMH) 90 participants Est. completion 2030-04-11 1 site
    Other conditions: Alzheimer s Disease, Mild Cognitive Impairment, Healthy
    View official trial listing →
  • Recruiting NCT NCT07787169

    A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

    Not yet reported Eli Lilly and Company 179 participants Est. completion 2028-07 18 sites
    Other conditions: Alzheimer Disease, Amyloid, Plaque, Amyloid, Healthy Volunteers
    View official trial listing →
  • Recruiting NCT NCT07787182

    A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

    Not yet reported Eli Lilly and Company 68 participants Est. completion 2028-01 18 sites
    Other conditions: Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
    View official trial listing →
  • Terminated NCT NCT02362880

    Study of Genetic Alzheimer's Disease Mutation Carriers in Preclinical Stages of the Disease 18F-Florbetaben Positron Emission Tomography Study

    Not yet reported Judit Pich Martínez 32 participants Est. completion 2019-01 1 site
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT02531360

    Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies

    Not yet reported Molecular NeuroImaging 7 participants Est. completion 2016-08 1 site
    Other conditions: Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP), Cortical Basal Syndrome (CBS), Frontal Temporal Dementia (FTD)
    View official trial listing →
  • Completed NCT NCT02556502

    18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study

    Not yet reported Central Hospital, Nancy, France 40 participants Est. completion 2017-11 1 site
    Other conditions: Amyloid PET Imaging
    View official trial listing →
  • Withdrawn NCT NCT02664571

    Florbetaben as an Amyloid Plaque Marker in Elderly Patients With Focal or Disseminated Superficial Hemosiderosis

    Not yet reported Centre Hospitalier Universitaire de Nīmes Est. completion 2021-07 2 sites
    Other conditions: Amyloid Cerebral Angiopathy, Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT02669225

    Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People

    Not yet reported National Institute on Alcohol Abuse and Alcoholism (NIAAA) 22 participants Est. completion 2018-07-11 1 site
    Other conditions: Normal Physiology
    View official trial listing →
  • Completed NCT NCT02681172

    Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD

    Not yet reported Lantheus Biosciences Ltd. 218 participants Est. completion 2016-11 1 site
    Other conditions: Alzheimer's Disease (AD)
    View official trial listing →
  • Completed NCT NCT02831283

    Imaging Inflammation in Alzheimer's Disease

    Not yet reported Patrick Lao 60 participants Est. completion 2022-12 1 site
    Other conditions: Alzheimer's Disease
    View official trial listing →
  • Withdrawn NCT NCT03057938

    Subjects With Subjective Cognitive Decline: 18F-Florbetaben Positron Emission Tomography Study

    Not yet reported Fundacion Clinic per a la Recerca Biomédica Est. completion 2022-06
    Other conditions: Subjective Cognitive Decline
    View official trial listing →
  • Completed NCT NCT03075007

    Brain Vascular Disease in Aging and Dementia

    Columbia University 48 participants Est. completion 2019-08-31 1 site
    Other conditions: Alzheimer Disease, White Matter Hyperintensities, Dementia, Aging
    View official trial listing →
  • Completed NCT NCT03119558

    PET/MRI Evaluation of Cardiac Amyloid

    Not yet reported Stanford University 9 participants Est. completion 2018-08-28 1 site
    Other conditions: Cardiac Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT03507257

    Longitudinal Early-onset Alzheimer's Disease Study Protocol

    Indiana University 850 participants Est. completion 2027-01-01 23 sites
    Other conditions: Early Onset Alzheimer Disease, Alzheimer Disease, Mild Cognitive Impairment
    View official trial listing →
  • Completed NCT NCT03616496

    Assessment of 18F-Florbetaben Whole-body PET for the Detection of Cardiac and Extracardiac Sites of Amyloid Deposits

    Not yet reported Central Hospital, Nancy, France 67 participants Est. completion 2025-02-10 1 site
    Other conditions: Cardiac Amyloidosis
    View official trial listing →
  • Completed NCT NCT03706261

    Alzheimer's PET Imaging in Racially/Ethnically Diverse Adults

    Not yet reported Adam Brickman 145 participants Est. completion 2023-07-14 1 site
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT03744312

    Imaging Inflammation in Alzheimer's Disease With 11C-ER176

    Not yet reported, Not yet reported Columbia University 9 participants Est. completion 2022-07-20 1 site
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT03779815

    Detection of Amyloidosis in Multiple Myeloma Patients by [18F]Florbetaben Positron Emission Tomography

    Not yet reported Ulsan University Hospital 14 participants Est. completion 2019-02-28 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT04055532

    Biomarkers in Neurodegenerative Diseases

    University of Minnesota Est. completion 2025-10-01 1 site
    Other conditions: Mild Cognitive Impairment (MCI), Alzheimer Disease (AD), Dementia With Lewy Bodies (DLB), Frontotemporal Lobar Degeneration (FTLD), Parkinsons Disease With Dementia (PDD), Transient Epileptic Amnesia (TEA), Temporal Lobe Epilepsy (TLE), Spinocerebellar Ataxias (SCA), HIV Associated Neurocognitive Disorder (HAND), Amyotrophic Lateral Sclerosis (ALS), Primary Lateral Sclerosis (PLS)
    View official trial listing →
  • Terminated NCT NCT04105634

    Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT

    Not yet reported University of Pennsylvania 3 participants Est. completion 2024-10-14 1 site
    Other conditions: Cardiac Amyloidosis
    View official trial listing →
  • Completed NCT NCT04392960

    Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis

    Not yet reported Fondazione IRCCS Policlinico San Matteo di Pavia 30 participants Est. completion 2025-06-30 1 site
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Completed NCT NCT04510168

    Accelerated Non-Atherosclerotic Brain Arterial Aging Relationship to Alzheimer's Disease

    Jose Gutierrez, MD, MPH 238 participants Est. completion 2024-04-17 1 site
    Other conditions: Alzheimer Disease, Dementia
    View official trial listing →
  • Completed NCT NCT04720001

    Florbetaben PET Imaging in PPA

    University of Chicago 1 participants Est. completion 2021-02-26 1 site
    Other conditions: Primary Progressive Aphasia, Alzheimer Disease
    View official trial listing →
  • Active, not recruiting NCT NCT04840979

    Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease

    Not yet reported Columbia University 107 participants Est. completion 2026-12 1 site
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Status unknown NCT NCT05147532

    Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation

    Not yet reported Assistance Publique - Hôpitaux de Paris 80 participants Est. completion 2024-05 1 site
    Other conditions: Multiple Sclerosis, Inflammatory Disease
    View official trial listing →
  • Completed NCT NCT05184088

    Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

    Not yet reported Lantheus Germany GmbH 244 participants Est. completion 2026-05-05 14 sites
    Other conditions: Cardiac Amyloidosis, AL Amyloidosis, ATTR Amyloidosis
    View official trial listing →
  • Completed NCT NCT05270083

    Neuraceq™ PET for Detection of Brain Changes in Young Athletes Post-concussion

    Not yet reported Dartmouth-Hitchcock Medical Center 15 participants Est. completion 2019-10-10 1 site
    Other conditions: Concussion, Brain
    View official trial listing →
  • Terminated NCT NCT05337774

    Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury

    Not yet reported Life Molecular Imaging SA. 18 participants Est. completion 2022-04-30 1 site
    Other conditions: Mild Traumatic Brain Injury
    View official trial listing →
  • Active, not recruiting NCT NCT05361382

    Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

    Not yet reported Tharick Pascoal 822 participants Est. completion 2027-05-31 9 sites
    Other conditions: Alzheimer Disease
    View official trial listing →
  • Completed NCT NCT05527288

    A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population

    Not yet reported Sinotau Pharmaceutical Group 50 participants Est. completion 2021-09-12 1 site
    Other conditions: Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
    View official trial listing →
  • Enrolling by invitation NCT NCT05617014

    Alzheimer's Disease Neuroimaging Initiative 4

    University of Southern California 1500 participants Est. completion 2027-07-31 65 sites
    Other conditions: Mild Cognitive Impairment, Alzheimer Disease, Dementia
    View official trial listing →
  • Completed NCT NCT05783934

    Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Amyloid PET-CT

    Not yet reported Istituti Clinici Scientifici Maugeri SpA 6 participants Est. completion 2024-01-09 1 site
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Status unknown NCT NCT06048601

    18F-florbetaben PET-CT to Non-invasively Diagnose Cardiac AL Amyloidosis

    Not yet reported Fondazione Toscana Gabriele Monasterio 150 participants Est. completion 2025-01-31 1 site
    Other conditions: Amyloid, Amyloid Cardiomyopathy
    View official trial listing →
  • Not yet recruiting NCT NCT06330077

    Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis

    Not yet reported Assistance Publique - Hôpitaux de Paris 60 participants Est. completion 2027-06 2 sites
    Other conditions: Multiple Sclerosis, Remitting Relapsing Multiple Sclerosis
    View official trial listing →
  • Completed NCT NCT06790394

    Test-retest Study With [18F]FBB in Cardiac Amyloidosis

    Not yet reported Lantheus Germany GmbH 15 participants Est. completion 2026-10-07 2 sites Stand-alone
    Other conditions: Cardiac Amyloidosis
    View official trial listing →
  • Not yet recruiting NCT NCT07624760

    Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging

    Not yet reported University of Zurich 50 participants Est. completion 2028-05 1 site
    Other conditions: Monoclonal Gammopathy, Monoclonal Gammopathy of Undetermined Significance (MGUS), Multiple Myeloma, AL Amyloidosis, Systemic Amyloidosis
    View official trial listing →
  • Enrolling by invitation NCT NCT07758660

    Alzheimer's Disease Research Center (ADRC) PET Component Study

    Not yet reported Patrick Lao 120 participants Est. completion 2033-05-31 1 site
    Other conditions: Alzheimer Disease, Mild Cognitive Impairment (MCI), Dementia
    View official trial listing →
  • Not yet recruiting NCT NCT07843459

    A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)

    Not yet reported Eli Lilly and Company 111 participants Est. completion 2028-07 18 sites
    Other conditions: Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid, Plasma
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.